AstraZeneca and Bristol Myers Squibb (BMS) are in discussions regarding a potential merger. If the deal goes through, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion, ranking as the world's fourth-largest drugmaker and one of the largest mergers in the history of the pharmaceutical industry.
According to a report by the Financial Times on August 2, sources familiar with the matter revealed that the two companies have held multiple rounds of consultations over the past few months regarding a merger. The deal is expected to be finalized soon, but there is also a possibility of delays or collapse. AstraZeneca is currently valued at approximately £196 billion, while BMS has a market cap of around $133 billion. A combined entity would have a total market value close to $400 billion.
If confirmed, the news of these talks will have a profound impact on the stock prices of both companies and the broader pharmaceutical sector. BMS shares have risen 21% year-to-date, while AstraZeneca shares have fallen 8% over the same period. Meanwhile, the deal could trigger heightened political concerns in the UK about the "exodus" of one of its most valuable listed companies, and it will face rigorous scrutiny from regulatory authorities in both countries.
Unprecedented Deal Size, Structural Details Pending
According to reports, this potential merger would be the largest acquisition in AstraZeneca's history, far surpassing its 2021 purchase of rare disease biotech company Alexion for $39 billion. The specific structure of the deal has yet to be determined, but it is expected to involve both cash and stock payments.
AstraZeneca is the second-largest listed company by market cap in the UK and completed a direct listing in New York last June, a move that was already seen as a blow to the London Stock Exchange. If the merger ultimately leads AstraZeneca to relocate its domicile to the US, it would further exacerbate concerns in the UK about domestic flagship companies "fleeing" the country.
For AstraZeneca, the merger has clear strategic intent. The company has set an ambitious goal of achieving $80 billion in revenue by 2030, but its revenue last year was $58.7 billion, leaving a significant growth gap. AstraZeneca already generates nearly half of its revenue from the US market, and further deepening its presence in the US is a key pathway to achieving this target.
AstraZeneca's long-time CEO, Sir Pascal Soriot, told reporters in a conference call last week that the company "does not need M&A to achieve" its 2030 revenue goal. However, the revelation of these talks shows that the company is still actively exploring external expansion avenues beyond organic growth. Soriot famously resisted Pfizer's takeover bid for AstraZeneca over a decade ago, when Pfizer's offer was around £70 billion in 2014.
For Bristol Myers Squibb, the urgency of the merger is equally significant. The company acquired biotech firm Celgene for $74 billion in 2019, but the deal failed to deliver the expected returns, leaving it regarded as a laggard in the industry. More pressingly, multiple core drugs from BMS are approaching the end of their patent life, exposing the company to the risk of substantial revenue loss.
Bristol Myers Squibb also has a large oncology business, overlapping significantly with AstraZeneca's leading position in the oncology field. This overlap provides a basis for synergies from the merger but will also become a focal point of antitrust scrutiny.
However, reports indicate that the obstacles to this cross-border deal should not be underestimated. On the antitrust front, both companies have substantial oncology operations, and the combined market concentration will draw close attention from regulators. That said, the Trump administration has recently shown a more lenient stance toward mergers, pushing the US M&A market to near-record levels, which provides a somewhat favorable external environment for the deal.
On the political front, the deal will face scrutiny from both sides of the Atlantic. The UK is particularly sensitive—AstraZeneca is one of the UK's most representative listed companies, and any arrangement that could lead to its relocation to the US will provoke strong backlash within British political circles.
Comments